Symbiotec Pharma Hits New High, Jumps 20% on Q2 Results, Order Win

Symbiotec’s Strong Quarter Meets a Long-Term Fermentation Deal

Earnings growth and a 10-year manufacturing agreement have put the recently listed drugmaker’s capacity, execution and new-business plans in focus.

Profit growth outpaced revenue in Q2

Symbiotec’s consolidated profit after tax rose 169 per cent year on year to ₹52 crore in Q2 FY27, while revenue from operations increased 43 per cent to ₹280 crore. EBITDA climbed 88 per cent to ₹94 crore. The company said this measure excludes a one-time IPO expense of ₹3 crore, a distinction investors should keep in mind when assessing operating performance.

The API business, a core part of the company’s current operations, recorded a 16 per cent rise in operating revenue to ₹227 crore. Segment EBITDA grew 21 per cent to ₹71 crore. This was solid growth, though slower than the company-wide increases, making it useful to track whether newer activities add to the existing business without weakening its performance.

A decade-long agreement opens a new avenue

The company has entered a 10-year, take-or-pay contract development and manufacturing agreement with a European alternative protein innovator. It reserves dedicated capacity for the partner at Symbiotec’s Ujjain campus. Production is set to begin at an existing facility, followed by a dedicated plant with fermentation capacity of several hundred thousand litres. Contracted expansion options could take the programme into the millions of litres.

A take-or-pay structure and reserved capacity can provide greater visibility over facility use than relying solely on spot demand. But the announcement does not disclose the contract’s value or expected revenue contribution. The commercial significance will therefore depend on execution, the timing of the new plant and how effectively the reserved capacity is brought into operation.

Capex is central to the growth plan

Symbiotec spent ₹113 crore on capital expenditure in the first half of the fiscal year and projected full-year gross capex of ₹1,672 crore. It said ₹1,000 crore, or 61 per cent of that total, is being invested in new revenue-generating businesses. The company expects revenue generation from various new businesses to begin over the next 6–12 months.

That investment could broaden the company’s revenue base, but it also raises the importance of commissioning timelines and utilisation. Spending on capacity does not itself guarantee returns: investors will want to see the new assets attract business and contribute revenue as planned. The latest agreement offers a potential route to demand for part of the expansion, but its financial contribution remains unspecified.

A sharp market response raises the execution bar

Shares rose as much as 20 per cent to ₹1,525.80, the upper price band and an all-time high. At 2.23 pm, they were up 18.4 per cent at ₹1,505.20, while the Nifty 50 gained 1.13 per cent. Since listing at ₹988, the stock has advanced 54 per cent. The move indicates a strong response to the results and contract, but it also means the market has quickly recognised the growth story.

For investors, the next test is whether reported earnings momentum can be sustained as capital spending rises and new businesses start contributing. The stock’s sharp advance is not, by itself, evidence that future plans will deliver; monitoring operating results and disclosed progress on capacity will be important.

Key Highlights

• Q2 FY27 revenue from operations increased 43 per cent to ₹280 crore.
• Consolidated PAT rose 169 per cent to ₹52 crore; EBITDA advanced 88 per cent to ₹94 crore, excluding a one-time IPO expense.
• API operating revenue grew 16 per cent to ₹227 crore, with segment EBITDA up 21 per cent.
• A 10-year take-or-pay agreement reserves capacity for a European alternative protein partner.
• Full-year gross capex is projected at ₹1,672 crore, including ₹1,000 crore for new revenue-generating businesses.

Investor Note: Symbiotec’s results and long-term manufacturing agreement strengthen its growth narrative, but the contract’s value has not been disclosed and substantial planned capex must still translate into operating revenue. Investors may want to assess execution and future disclosures alongside the stock’s sharp rise, rather than treating the announcement as a guarantee of returns.